Roche Global Development: Clinical Trials

3 trials sponsored by Roche Global Development, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 withdrawn. 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 23Completed 2, Withdrawn 1

Follow Roche Global Development: new trials by email

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Targeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures
Atezolizumab 1200 mg IV, Tiragolumab 600 mg IV - Metastatic Cancer Lung, Advanced Lung Cancer
Phase 2WithdrawnGustave Roussy, Cancer Campus, Grand Paris2025-01-302026-03-23
Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer
oxaliplatin, capecitabine - Gastric Cancer, Esophageal Cancer
Phase 2CompletedUniversity of Southern California752004-12-282026-07-30
Tarceva and Capecitabine for Pancreatic Cancer
Capecitabine, OSI-774 - Pancreatic Cancer, Neoplasm Metastasis
Phase 2CompletedDana-Farber Cancer Institute322003-10-012009-11-02

Conditions studied

Esophageal Neoplasms (1)  ·  Lung Neoplasms (1)  ·  Neoplasm Metastasis (1)  ·  Pancreatic Neoplasms (1)  ·  Stomach Neoplasms (1)

Interventions

Capecitabine (2)  ·  Erlotinib Hydrochloride (1)  ·  Oxaliplatin (1)  ·  Tiragolumab (1)  ·  atezolizumab (1)

Countries

United States (2)

Top investigators

Matthew Kulke, MD (1)  ·  Syma Iqbal, M.D. (1)

NIH funding

2023 (1)